IRIS - Res&Arch Institutional Research Information System - Research & Archive

IORIO, Alfonso
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.813
EU - Europa 7.681
AS - Asia 3.041
SA - Sud America 237
AF - Africa 29
OC - Oceania 21
Continente sconosciuto - Info sul continente non disponibili 15
Totale 20.837
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.485
IE - Irlanda 1.759
UA - Ucraina 1.693
SG - Singapore 1.396
IT - Italia 908
SE - Svezia 847
RU - Federazione Russa 788
HK - Hong Kong 633
FI - Finlandia 503
DE - Germania 493
VN - Vietnam 493
CA - Canada 303
GB - Regno Unito 251
CN - Cina 239
BR - Brasile 196
TR - Turchia 108
FR - Francia 80
CH - Svizzera 69
UZ - Uzbekistan 49
AT - Austria 48
PL - Polonia 46
NL - Olanda 33
BE - Belgio 29
CZ - Repubblica Ceca 29
RO - Romania 28
LB - Libano 25
GR - Grecia 20
PT - Portogallo 19
CO - Colombia 18
JP - Giappone 16
AU - Australia 15
MX - Messico 15
EU - Europa 14
AE - Emirati Arabi Uniti 10
AR - Argentina 9
ES - Italia 9
IQ - Iraq 9
KR - Corea 9
BG - Bulgaria 8
AM - Armenia 7
EC - Ecuador 6
IN - India 6
NZ - Nuova Zelanda 6
PK - Pakistan 6
LT - Lituania 5
MA - Marocco 5
TW - Taiwan 5
ZA - Sudafrica 5
EG - Egitto 4
ID - Indonesia 4
LU - Lussemburgo 4
OM - Oman 4
PH - Filippine 4
IL - Israele 3
KZ - Kazakistan 3
NP - Nepal 3
PA - Panama 3
TN - Tunisia 3
BD - Bangladesh 2
CL - Cile 2
CR - Costa Rica 2
DZ - Algeria 2
ET - Etiopia 2
GH - Ghana 2
GL - Groenlandia 2
HN - Honduras 2
KE - Kenya 2
NO - Norvegia 2
RS - Serbia 2
SA - Arabia Saudita 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
UY - Uruguay 2
VE - Venezuela 2
CI - Costa d'Avorio 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
GE - Georgia 1
HR - Croazia 1
HU - Ungheria 1
IR - Iran 1
KG - Kirghizistan 1
LV - Lettonia 1
MC - Monaco 1
MK - Macedonia 1
MM - Myanmar 1
MY - Malesia 1
PE - Perù 1
PY - Paraguay 1
SC - Seychelles 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 20.837
Salva come PNG Salva come JPEG
Città #
Dublin 1.758
Chandler 1.691
San Mateo 1.102
Jacksonville 768
Singapore 752
Boardman 655
Hong Kong 629
Santa Clara 490
Dong Ket 489
Medford 489
Princeton 486
Wilmington 366
Altamura 362
Andover 345
Lawrence 283
Perugia 272
Ottawa 266
Ann Arbor 242
Des Moines 135
Saint Petersburg 130
Moscow 113
Norwalk 108
Izmir 104
Ashburn 96
Beijing 89
Helsinki 80
Shanghai 76
Falls Church 55
San Paolo di Civitate 54
Los Angeles 50
Woodbridge 37
Redwood City 31
Brussels 28
Amelia 25
New York 24
San Diego 24
Dearborn 22
Milan 21
Redmond 21
Bucharest 20
Den Haag 19
Auburn Hills 18
Frankfurt Am Main 18
Munich 18
Nuremberg 18
Chicago 16
London 16
Narni 16
Terni 16
Bogotá 15
Rome 15
Brno 13
São Paulo 13
Cardiff 12
Lausanne 12
Warsaw 11
Houston 10
Kiev 10
Rio de Janeiro 10
Dubai 9
Hanover 9
Amsterdam 8
Falkenstein 8
Frankfurt am Main 8
Seoul 8
Tokyo 8
Vienna 8
Bethesda 7
Dallas 7
Edinburgh 7
Philadelphia 7
Simi Valley 7
Yerevan 7
Belo Horizonte 6
Hamilton 6
Lappeenranta 6
Porto 6
Stockholm 6
College Station 5
Guangzhou 5
Tashkent 5
Timisoara 5
Wilmot 5
Ashton-under-Lyne 4
Auckland 4
Braga 4
Brasília 4
Curitiba 4
Fremont 4
Goiânia 4
Iowa City 4
Lisbon 4
Luxembourg 4
Madrid 4
Manassas 4
Melbourne 4
Poli 4
Silver Spring 4
Sofia 4
Tappahannock 4
Totale 13.295
Salva come PNG Salva come JPEG
Nome #
Aryl hydrocarbon receptor control of a disease tolerance defence pathway. 134
Oral anticoagulant therapy with POC device and remote computer monitoring in the setting of the Italian National Health System (INHS) 125
1286 Prospective consecutive cases of venous thromboembolic diseases at the single Venous thromboembolic Unit of Reggio Emilia 125
Interventions for enhancing medication adherence. 125
IDO1 suppresses inhibitor development in hemophilia A treated with factor VIII 100
Absence of Interaction Between Influenza Vaccination and Oral Anticoagulant Therapy: A Randomized Blinded Clinical Trial 92
Applied pharmacoeconomics: considerations to drive the choice of a prophylactic antithrombotic regimen 90
Establishing the prevalence and prevalence at birth of hemophilia in males a meta-analytic approach using national registries 87
Le trombofilie acquisite 86
Serine base exchange enzyme in commercially available porcine lyophilised platelets: different effect of unfractionated and low molecular weight heparins 86
Effect of dermatan sulphate on activated partial thromboplastin time determined with different reagents 86
Answering relevant research questions via careful observation of clinical practice: a fresh look at the old way forward. 86
I disordini congeniti ed acquisiti dell’emostasi e della fibrinolisi 85
Thrombophilia and cerebral vein thrombosis 84
Prothrombin 202120A mutation in Behcet’s disease 82
. The role of thrombophilic states in the bleeding tendency of patients with hemophilia 81
Safety and Efficacy of Ximelagatran: Meta-Analysis of the Controlled Randomized Trials for the Prophylaxis or Treatment of Venous Thromboembolism 81
LMWH or Ximelagatran versus VKA in the prevention of VTE after major knee surgery: a meta-analysis of randomized controlled trials 80
Are placebo-controlled trials ethical in areas where current guidelines recommend therapy? No 80
OAT with POC devices and remote computer monitoring in the setting of the Italian NHS: a controlled clinical trial 79
IMMUNE TOLERANCE INDUCTION (ITI) IN PATIENTS WITH HEMOPHILIA A AND INHIBITORS: THE ITALIAN RETROSPECTIVE-PROSPECTIVE REGISTRY - THE PROFIT STUDY 78
Audit clinico sull’impiego di plasma fresco congelato (PFC) in Umbria: disegno dello studio e risultati preliminari. 78
Development and validation of the first treatment satisfaction scale for adult haemophiliacs (Hemo0-SatA) 78
APTT evaluation in the presurgery screening: survey of 5000 patients 77
ANTITHROMBOTIC PROPHYLAXIS IN ELDERLY PATIENTS ATRIAL FIBRILLATION ADMITTED TO INTERNAL MEDICINE WARDS IN ITALY: ADHERENCE TO GUIDELINES 77
Sindrome da anticorpi fosfolipidi. Descrizione di un caso clinico con trombosi atriale dx e revisione della casistica di Reggio Emilia 76
Audit of the clinical use of fresh-frozen plasma in Umbria: study design and results of the pilot phase. 76
Prolonged antithrombin activity of low-molecular-weight heparins. Clinical implications for the treatment of thromboembolic diseases 75
Clinical validation of a new algorithm for computerized dosing of vitamin K antagonist therapy: a retrospective simulation study. 75
Low-molecular-weight-heparin for the long term treatment of symptomatic venous thromboembolism: meta-analysis of the randomized comparisons with oral anticoagulant 74
Italian Registry of Haemophilia and Allied Disorders. Objectives, methodology and data analysis. 74
Acute ketoacidosisin continuous subcutaneous insulin infusion treated Type 1 diabetics impairs the fibrynolytic capacity 74
A decisional model to individualize warfarin recommendations: Expected impact on treatment and outcome rates in a real-world population with atrial fibrillation 74
L’organizzazione del centro per il monitoraggio della terapia anticoagulante orale 73
Influenza vaccination in patients on long-term anticoagulant therapy. 73
Il monitoraggio della terapia anticoagulante orale 72
ACP Journal Club. A 9-factor score predicted 2-year risk for bleeding in outpatients with, or at high risk for, atherothrombosis. 72
Bioequivalence of B-domain deleted and plasma derived FVIII concentrates. 72
Sustained suppression of hepatitics C by pegylated Interferon (PEG-INF) and Ribavirin in hemophilic patients 71
Terapia anticoagulante orale con l’impiego di tecnologia POC e monitoraggio via web nell’ambito del Sistema Sanitario Nazionale Italiano 71
Genima study: genetic polymorphysms and myocardial infarction among italian young adults 71
HAEMOPHILIA MANAGEMENT THROUGH AN INTER-REGIONAL NETWORK IN MIDDLE ITALY 71
Comparison of the rates of joint arthroplasty in patients with severe factor VIII and IX deficiency: an index of different clinical severity of the 2 coagulation disorders. 71
RANDOMISED, OPEN, PROSPECTIVE, MULTICENTER PILOT STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ACTIVATED RECOMBINANT FACTOR VIIA (NOVOSEVEN) IN ACUTE INTRACEREBRAL HAEMORRHAGE IN PATIENTS TREATED WITH ORAL ANTICOAGULANT OR ANTIPLATELET AGENTS 70
Acute ketoacidosisin continuous subcutaneous insulin infusion treated Type 1 diabetics impairs the fibrynolytic capacity 70
Critical appraisal of five international guidelines on fresh frozen plasma clinical use. 70
Systematic review of randomized controlled trials of prophylactic clotting factor concentrate in hemophilia 69
D-DIMER TO PREDICT THROMBOSIS RECURRENCE: COMPARISON OF AGGREGATE DATA AND INDIVIDUAL PATIENT DATA META-ANALYSES. 69
Adherence to antibiotic treatment guidelines and outcomes in the hospitalized elderly with different types of pneumonia 69
Studio GEMINA: ruolo dei polimorfismi genetici e dell'omocisteinemia nell'infarto del miocardico in giovani-adulti italiani 68
Audit of the clinical use of fresh-frozen plasma in umbria: study design and results. 68
D-DIMER TO PREDICT RECURRENCE AFTER A FIRST EPISODE OF UNPROVOKED VENOUS THROMBOEMBOLISM: COMPARISON OF AGGREGATE AND INDIVIDUAL PATIENT DATA META-ANALYSIS 68
Heparin reduces venous thromboembolism in neurosurgery but increases the risk of bleeding. (Iorio A, Agnelli G. Low molecular weight and unfractionated heparin for prevention of venous thromboembolism in neurosurgery: a metanalysis. Arch Intern Med. 2000;160:2327-2332) 67
Low-molecular-weight heparin treatment and cancer: pooled analysis of 908 patients treated for three months 67
ACP Journal Club. The Wells rule and a primary care rule were useful for ruling out deep venous thrombosis in primary care. 67
The association between venous thromboembolism and physical inactivity in everyday life 67
Interaction Between Influenza Vaccination and Oral Anticoagulant Therapy: A Randomized Blinded Clinical Trial. 67
Haemophilia A and B and other rare bleeding disorders: an Italian retrospective survey on the intracranial haemorrhagic episodes. 67
D-DIMER TO PREDICT THROMBOSIS RECURRENCE AFTER UNPROVOKED VENOUS THROMBOEMBOLISM: EFFECT OF PATIENT- AND D-DIMER-RELATED FACTORS ON RECURRENCE PREDICTION 67
A methodological survey of the analysis, reporting and interpretation of Absolute Risk ReductiOn in systematic revieWs (ARROW): a study protocol. 67
Low molecular weight heparin for prevention of venous thromboembolism in elective neurosurgery: a metanalysis 66
Gemina study:genetic polymorphysms and myocardial infarction among italian young adults 66
High efficacy of combined therapy with pegylated interferon plus ribavirin in patients with hemophilia and chronic hepatitis C 66
ANTIVIRAL THERAPY FOR CHRONIC HEPATITIS C IN HEMOPHILIA PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS 66
Risk factors for venous thromboembolism in patients undergoing elective neurosurgery 65
Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B 65
Seizures, headache and thrombocytopenia: diagnosis and treatment do not always come in a standard sequence 65
Indoleamina 2,3 diossigenasi e tolleranza al fattore VIII in pazienti affetti da emofilia a grave. 65
Development and evaluation of the population pharmacokinetic models for FVIII and FIX concentrates of the WAPPS-Hemo project 65
Clinical and laboratoristic performance evaluation of three point-of-care devices for INR determination (Coagucheck, ProTime, Harmony) 64
Prevention of venous thromboembolism after major orthhopedic surgery: summing up evidence about old and new antithrombotic agents 64
Oral Anticoagulants and small intestinal bacterial overgrowth 64
Impact of Thrombophilia on Risk of Arterial Ischemic Stroke or Cerebral Sinovenous Thrombosis in Neonates and Children: A Systematic Review and Meta-Analysis of Observational Studies 64
Case Report: Sequestro polmonare in un paziente con emofilia a grave HIV positivo. 64
Defective indoleamine 2,3-dioxygenase induction is associated with inhibitor development in severe hemophilia a patients carrying f8 gene null mutations. 64
Recombinant Factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with Haemophilia A and inhibitors. 64
Hyperhomcysteinemia and other thrombophilic factors in Italian patients with inflammatory bowel disease 63
Fattori prognostici di successo nell ‘Induzione di immunotolleranza (ITI) negli emofilici a con inibitore high-responding (HR). Uno score predittivo dal registro Italiano. 63
Joint use of cardio-embolic and bleeding risk scores in elderly patients with atrial fibrillation. 63
Influenza vaccination in patients on long-term anticoagulant therapy 63
Low-molecular-weight-heparin for the long term treatment of symptomatic venous thromboembolism: meta-analysis of the randomized comparison with oral anticoagulant 62
Profilassi della trombosi venosa profonda in neurochirurgia 62
The D-dimer (DD) Test to Establish the Duration of Anticoagulation after a First Unprovoked Episode of Venuos Thromboembolism (VTE); the Prospective Randomized 'Prolong' Study on behalf of the Italian Federation of Anticoagulation Clinics (FCSA) 62
THE HEMOPHILIA REGISTRY OF THE ITALIAN ASSOCIATION OF HEMOPHILIA CENTRES 62
AJP Journal Club: Perioperative LMW heparin does not reduce mortality after surgery more than unfractionated heparin in patients with cancer. 62
Mortality and causes of death in Italian persons with haemophilia, 1990-2007 61
Transition to a web-based architecture of the Italian hemophilia registry network. 61
INDOLEAMINA 2,3 DIOSSIGENASI E TOLLERANZA AL FATTORE VIII IN PAZIENTI AFFETTI DA EMOFILIA A GRAVE. 61
Eradicazione del virus C dell'epatite (HCV) dopo terapia combinata con Interferone Pegilato (PEG-INF) e Rivabirina in pazienti emofilici HIV negativi 60
Warfarin Optimal Duration Italian Trial Investigators. Three months versus one year of oral anticoagulant therapy for idiopatic deep venous thrombosis. 60
Antiviral treatment for chronic hepatitis C in patients with human immunodeficiency virus. 60
Indoleanmine 2,3-Dioxygenase and Peripheral Tolerance to Exogenous Factor XIII: A Multi-Centre Pilot Study 60
A Predictive Model for the Development of High-Responding Inhibitor In Children with Severe and Moderate Hemophilia A- Results of a Multicenter Cohort Study. 60
Immune tolerance induction for treating inhibitors in people with congenital haemophilia A or B. 60
Factor V Leiden and G20210A prothrombin allele are not associated with thrombosis in Behcet’s disease 59
Determinants of Mortality in Cerebral Hemorrhage Patients on Antithrombotic Treatment: Prospective Evaluation in the Italian Emergency Departments of a Multicentric Cohort of 1071 Patients 59
Systematic Review of Randomized Controlled Trials of Prophilactic Clotting Factor Concentrate in Hemophilia 59
AICE. FINAL RESULTS FROM THE ITALIAN ASSOCIATION OF HEMOPHILIA CENTERS (AICE) SURVEY ON THE CAUSES OF DEATH AMONG ITALIAN HEMOPHILIACS. 59
Venous thrombotic risk assessment among factor V Leiden carriers undergone a thrombophilic screening by different types of indications 59
Low-molecular-weight-heparin treatment and cancer: pooled analysis of 908 patients treated for three months and review of the literature 58
Totale 7.229
Salva come PNG Salva come JPEG
Categoria #
all - tutte 104.877
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 104.877
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020603 0 0 0 0 0 0 0 0 328 107 24 144
2020/20213.491 34 290 94 314 1.180 165 220 8 303 98 247 538
2021/20223.740 51 742 92 140 123 36 64 1.372 34 25 445 616
2022/20235.912 541 887 95 415 472 660 8 302 2.251 10 193 78
2023/20242.084 157 229 108 36 36 14 507 125 211 82 238 341
2024/20252.971 20 621 63 140 714 106 88 419 800 0 0 0
Totale 21.542